why choose us

First received: October 23, 2023

Clinical Trial: First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients

Study Status: Completed

Recruit Status: RECRUITING

Condition: Carcinoma, Ovarian Epithelial

Study Type: INTERVENTIONAL


Official Title: A Phase IV Trial to Confirm the Efficacy of Olaparib in Combination With Bevacizumab as Frontline Treatment of HRD Positive Ovarian Tumors

Brief Summary: The goal of this prospective, phase IV, multi-centre clinical trial is to to define the proportion of patients with advanced high grade epithelial ovarian cancer (EOC) HRD-positive who will be treated at first line with olaparib in combination with bevacizumab as maintenance and to describe their clinical and demographic characteristics.Other primary objective is to confirm, in a setting close to clinical practice, the efficacy of olaparib concomitant with bevacizumab as maintenance treatment after first-line…

Read more